Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
By N. Bulkmans, Johannes Berkhof, L. Rozendaal, F. van Kemenade, A. Boeke, S. Bulk, F. Voorhorst, R. Verheijen, K. V. Van Groningen, M. Boon and 4 more. The Lancet, 2007
654 citations recorded by the source corpus.
Subfields: Epidemiology, Obstetrics and Gynecology, Otorhinolaryngology
View Paper: https://www.semanticscholar.org/paper/e4006ac6e1ac743ccf05304e2d7122ebad997e6d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Otorhinolaryngology
Citations in the corpus
- Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older (2009, methodology): “9%).(18) This high sensitivity translates into a very high negative predictive value (reassurance) of the HPV detection assay, allowing for extending screening intervals for test negative women, who are typically the majority of participants in a screening programme.”